2seventy bio, Inc.

Good day, and thank you for standing by. Welcome to the 270Bio third quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Elizabeth Hicken, Head of Investor Relations. Please go ahead.

Thank you, Operator. This morning, 270Bio issued a press release on our third quarter 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 270Bio.com. Speaking on the call today are Nick Leshley, Chief Kairos Officer, Chip Baird, Chief Operating Officer, and Steve Bernstein, Chief Medical Officer. Philip Gregory, Chief Scientific Officer, is also on the line for the Q&A section. As a reminder, today's discussion will include forward-looking statements related to 270-Bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, timelines, and expectations, and statements regarding our financial condition, expectations, and other future financial results, among others. Actual results may differ materially due to various risks, uncertainties, and other factors, including those described in the risk factors section of our most recent Form 10-K and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. You are cautioned not to place any undue reliance on these forward-looking statements and, except as required by law, we undertake no obligation to update or revise any forward-looking statements. At this time, I would like to turn the call over to Nick Lushley. Nick?

Thank you, Liz. Good morning, everyone, and thank you for joining us as we discuss our third quarter results and business updates. While this quarter was challenging for 270 and the broader biotech markets, we continue to take actions to best position the business and our science for future success. In September, we made the difficult but necessary decision to reshape our organization to allow us to advance our pipeline and support our partners at BMS as they redouble their commercialization efforts with ABECMA. Chip will discuss in more detail. We continue to support BMS in their efforts to return ABECMA to growth and believe in the significant benefits it delivers for patients. We also look forward to presenting important data at the upcoming American Society of Hematology meeting. Steve will walk through what we saw in the abstracts from CARMA 3 and CARMA 2C presentations. In this environment, we have a sharp focus on the future, determining how to best ensure our important therapies become available to patients in need, drive value for our shareholders, and continue to do what's best for our employees. We are evaluating all options. to achieve these objectives. As always, I would like to thank our 270 team. I remain deeply grateful for our dedicated and talented employees who continue to go above and beyond to advance our programs and deliver for patients. I could not be more proud of the culture and the talent that we've built at 270. I will now hand it over to Chip to talk more about ABACMA and our Q3 results.